Mutations in β-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6248-6255

  Berrazeg, M ^a   Jeannot, K ^a   Ntsogo Enguéné, Véronique Yvette ^b   Broutin, I ^b   Loeffert, S ^a   Fournier, D ^a   Plesiat P ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE AMPC; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN DERIVATIVE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MOLECULAR TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; ADAPTATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR GENETICS; MUTATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

ADAPTATION, PHYSIOLOGICAL; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; AZTREONAM; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORINS; GENE EXPRESSION; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PENICILLANIC ACID; PIPERACILLIN; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PSEUDOMONAS AERUGINOSA; TICARCILLIN;

EID: 84941168496     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00825-15     Document Type: Article

References (41)

1. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582-610. http://dx.doi.org/10.1128/CMR.00040-09.
2. Sabath LD, Jago M, Abraham EP. 1965. Cephalosporinase and penicillinase activities of a β-lactamase from Pseudomonas pyocyanea. Biochem J 96:739-752.
3. Masuda N, Gotoh N, Ishii C, Sakagawa E, Ohya S, Nishino T. 1999. Interplay between chromosomal β-lactamase and the MexAB-OprM efflux system in intrinsic resistance to β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:400-402.
4. Livermore DM, Williams RJ, Lindridge MA, Slack RC, Williams JD. 1982. Pseudomonas aeruginosa isolates with modified beta-lactamase inducibility: effects on beta-lactam sensitivity. Lancet i:1466-1467.
5. Fung-Tomc J, Dougherty TJ, DeOrio FJ, Simich-Jacobson V, Kessler RE. 1989. Activity of cefepime against ceftazidime- and cefotaxime-resistant Gram-negative bacteria and its relationship to beta-lactamase levels. Antimicrob Agents Chemother 33:498-502. http://dx.doi.org/10.1128/AAC.33.4.498.
6. Moya B, Dötsch A, Juan C, Blazquez J, Zamorano L, Haussler S, Oliver A. 2009. β-Lactam resistance response triggered by inactivation of a non-essential penicillin-binding protein. PLoS Pathog 5:e1000353. http://dx.doi.org/10.1371/journal.ppat.1000353.
7. Cabot G, Ocampo-Sosa AA, Dominguez MA, Gago JF, Juan C, Tubau F, Rodriguez C, Moyà B, Pena C, Martinez-Martinez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2012. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 56:6349-6357. http://dx.doi.org/10.1128/AAC.01388-12.
8. Castanheira M, Mills JC, Farrell DJ, Jones RN. 2014. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother 58:6844-6850. http://dx.doi.org/10.1128/AAC.03681-14.
9. Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. 2007. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51:4062-4070. http://dx.doi.org/10.1128/AAC.00148-07.
10. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2011. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906-1911. http://dx.doi.org/10.1128/AAC.01645-10.
11. Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, Marty N, Grattard F, Mariani-Kurkdjian P, Bingen E, Husson M-O, Couedic G, Plésiat P. 2007. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 51:3531-3536. http://dx.doi.org/10.1128/AAC.00503-07.
12. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 54:1213-1217. http://dx.doi.org/10.1128/AAC.01104-09.
13. Mushtaq S, Warner M, Livermore DM. 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other nonfermenters. J Antimicrob Chemother 65:2376-2381. http://dx.doi.org/10.1093/jac/dkq306.
14. Jacoby GA. 2009. AmpC β-lactamases. Clin Microbiol Rev 22:161-182. http://dx.doi.org/10.1128/CMR.00036-08.
15. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. 2014. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 58:5704-5713. http://dx.doi.org/10.1128/AAC.03057-14.
16. Holloway BW. 1955. Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 13:572-581. http://dx.doi.org/10.1099/00221287-13-3-572.
17. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tomkins RG, Ausubel FM. 1995. Common virulence factors for bacterial pathogenicity in plants and animals. Science 268:1899-1902. http://dx.doi.org/10.1126/science.7604262.
18. Bryan LE, Kwan S, Godfrey AJ. 1984. Resistance of Pseudomonas aeruginosa mutants with altered control of chromosomal β-lactamase to piperacillin, ceftazidime, and cefsulodin. Antimicrob Agents Chemother 25:382-384. http://dx.doi.org/10.1128/AAC.25.3.382.
19. Richardot C, Plésiat P, Fournier D, Monlezun L, Broutin I, Llanes C. 2015. Carbapenem resistance in cystic fibrosis strains of Pseudomonas aeruginosa as a result of amino acid substitutions in porin OprD. Int J Antimicrob Agents 45:529-532. http://dx.doi.org/10.1016/j.ijantimicag.2014.12.029.
20. West SE, Schweizer HP, Dall C, Sample AK, Runyen-Janecky LJ. 1994. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148:81-86. http://dx.doi.org/10.1016/0378-1119(94)90237-2.
21. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. 2004. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol 42:5644-5649. http://dx.doi.org/10.1128/JCM.42.12.5644-5649.2004.
23. Cabot G, Bruchmann S, Mulet X, Zamorano L, Moya B, Juan C, Haussler S, Oliver A. 2014. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58:3091-3099. http://dx.doi.org/10.1128/AAC.02462-13.
24. Dumas J-L, vanDelden C, Perron K, Köhler T. 2006. Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol Lett 254:217-225. http://dx.doi.org/10.1111/j.1574-6968.2005.00008.x.
25. Jo JTH, Brinkman FSL, Hancock REW. 2003. Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. Antimicrob Agents Chemother 47:1101-1111. http://dx.doi.org/10.1128/AAC.47.3.1101-1111.2003.
26. Rodriguez-Martinez JM, Poirel L, Nordmann P. 2009. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:1766-1771. http://dx.doi.org/10.1128/AAC.01410-08.
27. Tam VH, Schilling AN, LaRocco MT, Gentry LO, Lolans K, Quinn JP, Garey KW. 2007. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 13:413-418. http://dx.doi.org/10.1111/j.1469-0691.2006.01674.x.
28. Zamorano L, Moya B, Juan C, Oliver A. 2010. Differential β-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. J Antimicrob Chemother 65:1540-1542. http://dx.doi.org/10.1093/jac/dkq142.
29. Rodriguez-Martinez JM, Poirel L, Nordmann P. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:4783-4788. http://dx.doi.org/10.1128/AAC.00574-09.
30. Dahyot S, Broutin I, de Champs C, Guillon H, Mammeri H. 2013. Contribution of asparagine 346 residue to the carbapenemase activity of CMY-2. FEMS Microbiol Lett 345:147-153. http://dx.doi.org/10.1111/1574-6968.12199.
31. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. 2012. Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother 67:1354-1358. http://dx.doi.org/10.1093/jac/dks079.
32. Drawz SM, Taracila M, Caselli E, Prati F, Bonomo RA. 2011. Exploring sequence requirements for C3/C4 carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: insights into plasticity of the AmpC β-lactamase. Protein Sci 20:941-958. http://dx.doi.org/10.1002/pro.612.
33. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35:736-755. http://dx.doi.org/10.1111/j.1574-6976.2011.00268.x.
34. Fernandez-Olmos A, Garcia-Castillo M, Alba JM, Morosini MI, Lamas A, Romero B, Galan JC, del Campo R, Canton R. 2013. Population structure and antimicrobial susceptibility of both nonpersistent and persistent Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Clin Microbiol 51:2761-2765. http://dx.doi.org/10.1128/JCM.00802-13.
35. Garcia-Castillo M, Maiz L, Morosini MI, Rodriguez-Banos M, Suarez L, Fernandez-Olmos A, Baquero F, Canton R, del Campo R. 2012. Emergence of a mutL mutation causing multilocus sequence typing-pulsedfield gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient. J Clin Microbiol 50:1777-1778. http://dx.doi.org/10.1128/JCM.05478-11.
36. Warren AE, Boulianne-Larsen CM, Chandler CB, Chiotti K, Kroll E, Miller SR, Taddei F, Sermet-Gaudelus I, Ferroni A, McInnerney K, Franklin MJ, Rosenzweig F. 2011. Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections. Infect Immun 79:4802-4818. http://dx.doi.org/10.1128/IAI.05282-11.
37. Oliver A, Mena A. 2010. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin Microbiol Infect 16:798-808. http://dx.doi.org/10.1111/j.1469-0691.2010.03250.x.
38. Crémet L, Caroff N, Giraudeau C, Reynaud A, Caillon J, Corvec S. 2013. Detection of clonally related Escherichia coli isolates producing different CMY β-lactamases from a cystic fibrosis patient. J Antimicrob Chemother 68:1032-1035. http://dx.doi.org/10.1093/jac/dks520.
39. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254. http://dx.doi.org/10.1126/science.288.5469.1251.
40. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagace-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA. 2014. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 74:31-51. http://dx.doi.org/10.1007/s40265-013-0168-2.
41. Blizzard TA, Chen H, Kim S, Wu J, Young K, Park YW, Ogawa A, Raghoobar S, Painter RE, Hairston N, Lee SH, Misura A, Felcetto T, Fitzgerald P, Sharma N, Lu J, Ha S, Hickey E, Hermes J, Hammond ML. 2010. Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem. Bioorg Med Chem Lett 20:918-921. http://dx.doi.org/10.1016/j.bmcl.2009.12.069.